SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of hepatitis C virus (HCV) infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS. Full abstracts can be viewed at the EASL website at www.easl.eu.

“In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy”

SCY-635 Oral Presentation

"Resistance Selection Following 15 Days of Monotherapy with SCY-635 a Non-immunosuppressive Cyclophilin Inhibitor with Potent Anti-HCV Activity," Thursday, April 15, 2010, 17:45 to 18:00 CET.

SCY-635 Poster Presentations

"The Effects of SCY-635 a Non-immunosuppressive Cyclosporin Analog on Stellate Cell Proliferation, Collagen Synthesis, TIMP-1 and Collagenase Production," Friday, April 16, 2010

"In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy," Friday, April 16, 2010

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing drug discovery with SmartCADD